日本 RNA 療法市場評估：依類型、產品、適應症、最終用戶、地區、機會和預測（2018年度-2032年度）

日本 RNA 治療市場規模預計將從2024年度的14.0391億美元增至2032年度的31.2358億美元，預計在2025年度至2032年度的預測期內年複合成長率為 10.52%。各大學不斷增加的研究活動支持市場成長，包括推出支持政策、增加專利發放以及加強市場與區域公司之間的合作。隨著日本老化社會迅速擴大，醫療進步和健康問題意識不斷增強，導致新技術的採用。根據世界經濟論壇估計，日本超過十分之一的人年齡超過80歲。

日本加強個人化醫療的開發和可用性也推動了日本 RNA 治療市場的發展。2024年 7月，LSI Medience Corporation 和癌症基因組分析領先公司之一 ACT Genomics Co. Ltd. 宣布，雙方已簽署關於日本市場合作的諒解備忘錄。此次合作預計將為日本個人化醫療的發展做出巨大貢獻。最初，它將致力於將基因組分析整合到研究活動中，為研究人員提供個人化資訊。此類合作研究預計將推動日本 RNA 治療市場的發展。

此外，日本慢性病患者數量的增加也支持了市場的擴張。由於RNA結合蛋白通常結合多個轉錄物，因此靶向核糖核蛋白（RNP）可以幫助改善癌症和自體免疫疾病，其中RNA結合蛋白在不同轉錄物中發揮複雜的作用，有可能為系統性疾病（例如，癌症和自體免疫疾病）提供有效的治療解決方案。

此外，mRNA疫苗的日益普及也推動了日本對 RNA 療法的需求。在過去的幾年裡，mRNA疫苗透過確保針對傳染病的標靶疫苗的快速開發而顯示出巨大的潛力。此外，其模組化特性使其能夠透過簡單地改變編碼任何抗原的mRNA 序列來輕鬆適應不同的病原體。人們越來越認識到 mRNA 疫苗帶來的好處，加強了對研究活動的需求和投資，對市場擴張產生了積極影響。

本報告研究和分析了日本 RNA 治療市場，提供市場規模和預測、市場動態以及主要公司的狀況。

目錄

第1章 專案範圍與定義

第2章 研究方法

第3章 執行摘要

第4章 日本RNA治療市場展望（2018年度-2032年度）

• 市場規模分析與預測
  • 金額
  • 數量
• 市場佔有率分析與預測
  • 依類型
  • 依產品
  • 依適應症
  • 依最終用戶
  • 依地區
  • 市場佔有率分析：依公司（價值）（前5名公司及其他 -2024年度）
• 市場地圖分析（2024年）
  • 依類型
  • 依產品
  • 依適應症
  • 依最終用戶
  • 依地區

第5章 供需分析

第6章 進出口分析

第7章 價值鏈分析

第8章 波特五力分析

第9章 PESTLE分析

第10章 價格分析

第11章 市場動態

• 市場驅動因素
• 市場挑戰

第12章 市場趨勢與發展

第13章 監理架構與創新

• 臨床試驗
• 監理機關的核准

第14章 專利狀況

第15章 個案研究

第16章 競爭態勢

• 前5名市場領導者的競爭矩陣
• 前5名的公司的SWOT 分析
• 主要企業狀況
  • Pfizer Inc.
  • Moderna, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Biogen Inc.
  • NS Pharma, Inc.
  • Novartis Pharmaceuticals Corporation
  • Jazz Pharmaceuticals Plc
  • Arcturus Therapeutics Holdings Inc.

第17章 策略建議

第18章 關於本公司，免責聲明

Japan RNA therapeutics market is projected to witness a CAGR of 10.52% during the forecast period FY2025-FY2032, growing from USD 1,403.91 million in FY2024 to USD 3,123.58 million in FY2032. Rising research activities by various universities support the market's growth, the introduction of supportive government measures, increasing issuance of patents, and rising collaborations between market players and regional companies. Due to the rapid expansion of the aging population in Japan, the country is becoming more aware of medical developments and health challenges and adopting novel technologies. According to estimates from the World Economic Forum, over 1 in 10 people in Japan are 80 or older.

The increasing efforts to bolster the development and availability of personalized medicines in the country are also propelling the Japan RNA therapeutics market. In July 2024, LSI Medience Corporation and ACT Genomics Co. Ltd., one of the leaders in cancer genomic profiling, announced that they had signed a Memorandum of Understanding (MoU) to collaborate in the Japanese market. The partnership is expected to significantly contribute to the advancements of personalized medicines in Japan. It is initially going to focus on the integration of genomic profiling in research practices and provide researchers with personalized information. Such collaborations are expected to propel the Japan RNA therapeutics market.

Additionally, the rising cases of chronic diseases in the country are also supporting the market's expansion. The RNA-binding proteins usually bind with multiple transcripts, thus targeting ribonucleoproteins (RNPs) hold promise for delivering effective treatment solutions for systemic diseases including cancer and autoimmune disorders, among others, where an intricate role is played by RNA-binding proteins across diverse transcripts.

Furthermore, the growing popularity of messenger RNA (mRNA) vaccines is also bolstering the demand for Japan RNA therapeutics. Over the past few years, mRNA vaccines have shown significant potential by ensuring the rapid development of targeted vaccines for infectious diseases. Furthermore, their modular nature allows them to adapt easily to different pathogens by simply conducting alterations in the mRNA sequence that encodes the desired antigen. The growing awareness about such advantages associated with mRNA vaccines is bolstering their demand and investments towards research activities, positively influencing the market's expansion.

Supportive Government Measures Boost Market Expansion

The growing efforts of the government of Japan to support the development and availability of RNA therapeutics in the country are propelling the market's expansion. The government also provides grants to boost mRNA therapeutics and vaccine production. In August 2023, the government awarded USD 115 million in two separate grants to ARCALIS Inc., the manufacturing joint venture of Arcturus Therapeutics Holdings Inc. in Japan. The grants would be used to fund the mRNA drug product operations and the production of mRNA drug substances by allowing the purchase of capital equipment to support current Good Manufacturing Practices (cGMP) and the construction of a factory. Such efforts are expected to provide lucrative growth opportunities for the market in the coming years and bolster the availability of therapeutics that offer greater durability and high levels of efficacy.

Rising Issuance of Patents Supports Market Growth

The increasing issue of patents for nucleic acid extraction technologies for various companies in Japan is also expected to bolster the growth of the market. In March 2023, BioEcho Life Sciences GmbH, one of the leading biotechnology companies announced the issuance of two new patents by the Japan Patent Office, covering their EchoLUTION technology for extraction of nucleic acids. The EchoLUTION technology allows for the extraction of RNA and DNA in a single centrifugation step, resulting in the availability of inhibitor-free and high-quality RNA and DNA that is ready for downstream applications. Such patents aid in strengthening a company's intellectual property portfolio and foster innovations to ensure the availability of novel technologies. The issuance is also expected to transform different processes in biopharmaceutical research, molecular diagnostics, academics, and animal and plant breeding.

mRNA Therapeutics Account for Major Market Share

The rapid advancements in molecular medicine and biotechnology have bolstered the therapeutic applications of mRNA. mRNA is transcribed from a DNA strand, carrying coding information necessary for the synthesis of proteins so that it can be further processed and transcribed into functional proteins. The rising research activities by leading universities in the country is also expected to aid the segment's expansion. In March 2024, a team of researchers from the Tokyo Medical and Dental University (TMDU) announced that they had successfully developed a new method for chemically modifying engineered mRNA molecules, advancing mRNA therapeutic technologies and allowing greater control of the biological functions of RNA molecules. The mRNA technology holds significant potential for developing novel cancer vaccines and treatments and for treating a wide range of diseases that had earlier been deemed incurable. The development of such innovative techniques is expected to ensure significant advancements in the therapeutic applications of mRNA polyplexes.

Vaccine Segment Holds Major Market Share

mRNA vaccines introduce a piece of mRNA corresponding to the viral protein. The immune system produces antibodies as it recognizes the protein as a foreign substance, as part of a normal immune response. Antibodies aid in protecting the host against infections by recognizing individual pathogens and viruses and marking them for destruction. Upon production, the antibodies stay in the body even after the pathogen has been eliminated from the body, allowing the immune system to respond quickly in case of future exposures.

The rising approvals for RNA vaccines in Japan are expected to provide lucrative growth opportunities to the market in the coming years. In November 2023, the Ministry of Health, Labor and Welfare of Japan approved the first self-amplifying mRNA vaccine that Arcturus Therapeutics Holdings Inc. and CSL developed. Such approvals are expected to influence the market's expansion in the coming years positively.

Future Market Scenario (FY2025-FY2032F)

As per the Japan RNA therapeutics market analysis, the evolving requirements of the patient population in Japan due to the country's rapid aging and rising cases of chronic diseases are expected to bolster the demand for RNA therapeutics in Japan. The proven applications of RNAi in rare diseases, along with new developments that aid in targeting cancer, are also expected to positively influence the market's expansion.

Additionally, various research studies are also underway to evaluate the working and efficacy of different RNA therapeutics. For instance, Gilead Sciences, Inc. is conducting an interventional study to evaluate the antiviral activity of lenacapavir in patients with human immunodeficiency virus (HIV) (PWH) with multi-drug resistance. The study is expected to conclude in January 2027. Such studies are expected to provide lucrative growth opportunities for the market.

Key Players Landscape and Outlook

Increasing collaborations between leading market players and regional companies are expected to provide lucrative growth opportunities for the market. In July 2024, Mitsubishi Tanabe Pharma Corporation and Moderna, Inc. announced that they have entered into an agreement to promote latter's mRNA respiratory vaccine portfolio in the country. Under the agreement, both companies are going to engage in various activities to ensure the availability of Moderna's mRNA portfolio and make an impact on Japan's public health. The initial term of the agreement was listed on March 31, 2029. Such partnerships are expected to contribute towards enhancing the country's pharmaceutical sector and public health.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Japan RNA Therapeutics Market Outlook, FY2018-FY2032F

• 4.1. Market Size Analysis & Forecast
  • 4.1.1. By Value
  • 4.1.2. By Volume
• 4.2. Market Share Analysis & Forecast
  • 4.2.1. By Type
    • 4.2.1.1. RNA Interference (RNAi) Therapeutics
    • 4.2.1.2. mRNA Therapeutics
    • 4.2.1.3. Antisense Oligonucleotide (ASO)Therapeutics
    • 4.2.1.4. Others
  • 4.2.2. By Product
    • 4.2.2.1. Vaccines
    • 4.2.2.2. Drugs
  • 4.2.3. By Indication
    • 4.2.3.1. Rare Genetic Diseases/Hereditary Diseases
    • 4.2.3.2. Infectious Diseases
    • 4.2.3.3. Others
  • 4.2.4. By End-user
    • 4.2.4.1. Hospitals
    • 4.2.4.2. Academic Research Centers
    • 4.2.4.3. Contract Research Organizations
    • 4.2.4.4. Others
  • 4.2.5. By Region
    • 4.2.5.1. North [Hokkaido and Tohoku]
    • 4.2.5.2. Central [Kanto and Chubu]
    • 4.2.5.3. South [Kansai, Chugoku, Shikoku, and Kyushu & Okinawa]
  • 4.2.6. By Company Market Share Analysis (Top 5 Companies and Others - By Value, FY2024)
• 4.3. Market Map Analysis, FY2024
  • 4.3.1. By Type
  • 4.3.2. By Product
  • 4.3.3. By Indication
  • 4.3.4. By End-user
  • 4.3.5. By Region

5. Demand Supply Analysis

6. Import and Export Analysis

7. Value Chain Analysis

8. Porter's Five Forces Analysis

9. PESTLE Analysis

10. Pricing Analysis

11. Market Dynamics

• 11.1. Market Drivers
• 11.2. Market Challenges

12. Market Trends and Developments

13. Regulatory Framework and Innovation

• 13.1. Clinical Trials
• 13.2. Regulatory Approvals

14. Patent Landscape

15. Case Studies

16. Competitive Landscape

• 16.1. Competition Matrix of Top 5 Market Leaders
• 16.2. SWOT Analysis for Top 5 Players
• 16.3. Key Players Landscape for Top Market Players
  • 16.3.1. Pfizer Inc.
    • 16.3.1.1. Company Details
    • 16.3.1.2. Key Management Personnel
    • 16.3.1.3. Products and Services
    • 16.3.1.4. Financials (As Reported)
    • 16.3.1.5. Key Market Focus and Geographical Presence
    • 16.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisitions
  • 16.3.2. Moderna, Inc.
  • 16.3.3. Alnylam Pharmaceuticals, Inc.
  • 16.3.4. Biogen Inc.
  • 16.3.5. NS Pharma, Inc.
  • 16.3.6. Novartis Pharmaceuticals Corporation
  • 16.3.7. Jazz Pharmaceuticals Plc
  • 16.3.8. Arcturus Therapeutics Holdings Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

17. Strategic Recommendations

18. About Us and Disclaimer

List of Tables

• Table 1. Pricing Analysis of Products from Key Players
• Table 2. Competition Matrix of Top 5 Market Leaders
• Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. Japan RNA Therapeutics Market, By Value, In USD Million, FY2018-FY2032F
• Figure 2. Japan RNA Therapeutics Market, By Volume, In Thousand Doses, FY2018-FY2032F
• Figure 3. Japan RNA Therapeutics Market Share (%), By Type, FY2018-FY2032F
• Figure 4. Japan RNA Therapeutics Market Share (%), By Product, FY2018-FY2032F
• Figure 5. Japan RNA Therapeutics Market Share (%), By Indication, FY2018-FY2032F
• Figure 6. Japan RNA Therapeutics Market Share (%), By End-user, FY2018-FY2032F
• Figure 7. Japan RNA Therapeutics Market Share (%), By Region, FY2018-FY2032F
• Figure 8. By Type Map-Market Size (USD Million) & Growth Rate (%), FY2024
• Figure 9. By Product Map-Market Size (USD Million) & Growth Rate (%), FY2024
• Figure 10. By Indication Map-Market Size (USD Million) & Growth Rate (%), FY2024
• Figure 11. By End-user Map-Market Size (USD Million) & Growth Rate (%), FY2024
• Figure 12. By Region Map-Market Size (USD Million) & Growth Rate (%), FY2024